Hit, hold or fold? Unilever, GlaxoSmithKline, AstraZeneca shares

If I had to buy, sell or hold AstraZeneca, Unilever or GlaxoSmithKline shares, what would I do? Fool UK contributor Joe Clark shows his hand.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Three FTSE 100 dividend stocks have caught my attention lately for the wrong, and conversely, the right reasons. All are not having a great time of late, particularly Unilever (LSE: ULVR) and GlaxoSmithKline (LSE: GSK), whose shares have been two of the FTSE  100’s worst performers this last month.

But these are dividend giants, and with the chance of strong capital growth I thought it was time I had a closer look at these UK portfolio staples.

I am going to look at these stocks as if I was in a casino and I was dealt all three. What share would I hit again (buy more), hold (keep) and fold (sell)?

Hold

GSK has been one of the worst performers of the FTSE 100 in the last 12 months, and is trading at a material 25% discount to its peer group. Whilst it has been a disappointment for a fair amount of time now, with a price-to-earning (P/E) ratio (10.8x) and a yearly dividend yield (6.6%), I would not be selling!

It is not just the great income you can get from this stock, but there are catalysts that can get this share price back on track, such as good results on its Covid-19 vaccine candidate, which recently reached phase 2 trials. Therefore Mr. Dealer, I’d hold.

Fold

AstraZeneca’s (LSE: AZN) recent results and future guidance were good. A lot of what I think is positive news has been lost around the controversy of the vaccine, particularly with the EU questioning its efficacy in the over 65s and then doing a U-turn and blocking shipments of the vaccine to Australia.

Fourth-quarter pre-tax profit, revenue and core earnings per share rose, and it guided for growth in the low-teens for 2021. Its fourth-quarter profit before tax was $1.17 billion, significantly higher than the last year’s $240 million.

Positive news, yes… but I can’t see a catalyst to push the share price up in the near future. I like the stock but it would be my last choice of the three to take a position in right now. Mr. Dealer, fold.

Buy

Unilever is one of the world’s largest consumer goods companies (with brands like Ben & Jerry’s, Dove and Vaseline) and has seen its share price drop over 10% since February. Every day, almost a third of the global population (approximately 2.5 billion people) use Unilever products.

I think now is a good opportunity to start a position into a great company that should provide me with dividend income and growth. Unilever shares have been paying dividends since 1929, and it currently offers an attractive combination of dividend yield (3.8% as of March 2021) and dividend growth (a five-year average of 5.3%). Mr. Dealer, I’d buy.

Summary

In conclusion, I wouldn’t shy away from looking at adding any of these shares to my portfolio, as I think all offer a good chance of capital growth as well as dividend income. To me the recent declines in the share prices give a great opportunity to start a position or add some more. But when faced with the decision to hit, hold or fold, I would hit Unilever, hold Glaxo and sell Astra.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Joseph Clark has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »